Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05870748 · ClinicalTrials.gov registry record · Phase 2
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
A Phase 2 study, sponsored by Sutro Biopharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 600
- Enrollment target
NCT05870748: Clinical Trial Phase 2 study, sponsored by Sutro Biopharma.
NCT05870748 is a Phase 2 study that was terminated before completion, run by Sutro Biopharma. The registered enrollment target is 600 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (351% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05870748, a Phase 2 study, was terminated before completion, sponsored by Sutro Biopharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 600 participants
- Enrollment target
Study Summary
A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.
Primary Outcome
time between the date of first dose and the first date of documented progression or death
Interventions
- DRUG Paclitaxel
- DRUG Gemcitabine
- DRUG Pegylated liposomal doxorubicin
- DRUG Pegfilgrastim
- DRUG Luveltamab tazevibulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2023-07-12 |
| Est. Completion | 2025-08-26 |
| Phase | Phase 2 |
Why NCT05870748 stopped before completion
NCT05870748 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (351% higher).
The record links to 0 conditions, and to 5 interventions - of which Paclitaxel is the first listed.
NCT05870748 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05870748 about?
NCT05870748 is a clinical study titled "REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1". A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.
What is the current status of trial NCT05870748?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 600 participants. The study started on 2023-07-12. Estimated completion is 2025-08-26.
What interventions are being tested in trial NCT05870748?
The interventions under investigation include: Paclitaxel (DRUG), Gemcitabine (DRUG), Pegylated liposomal doxorubicin (DRUG), Pegfilgrastim (DRUG), Luveltamab tazevibulin (DRUG).
Who is sponsoring clinical trial NCT05870748?
This trial is sponsored by Sutro Biopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05870748's enrollment target sits among peer trials
600 53rd of 2000 higher than 1,945 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI